SCHEMBL3532040

SCHEMBL3532040

CCCNS(=O)(=O)CCc1ccc(N)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 6/20 0.56
CA1 P00915 4/20 0.56
CA9 Q16790 4/20 0.56
CA12 O43570 2/20 0.56
RECQL P46063 1/20 0.51
CA6 P23280 1/20 0.45
CA5A P35218 1/20 0.45
CA7 P43166 1/20 0.45
CA14 Q9ULX7 1/20 0.45
CA5B Q9Y2D0 1/20 0.45
MMP8 P22894 4/20 0.44
MMP12 P39900 4/20 0.44
MMP13 P45452 4/20 0.44
PRMT1 Q99873 1/20 0.43
GFER P55789 1/20 0.42
MMP1 P03956 1/20 0.42
MMP7 P09237 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2994450 0.84 CA1 (0.61) CA2CA1CA9CA12RECQL
SCHEMBL8586492 0.84 F10 (0.41) CA2CA1CA9CA12MMP8
SCHEMBL8907383 0.83 MEN1 (0.60) CA9CA12MMP8MMP12MMP13
SCHEMBL15652547 0.81 CA1 (0.57) CA2CA1CA9CA12RECQL
SCHEMBL1275321 0.79 RECQL (0.58) CA2CA1CA9CA12RECQL
Hydrochloric Acid SCHEMBL4731092 0.77 RECQL (0.61) CA2CA1CA9CA12RECQL
SCHEMBL6565154 0.77 SMN1; SMN2 (0.50) CA2CA1CA9CA12CA5A
SCHEMBL9800414 0.75 MMP8 (0.55) CA2CA1CA9CA12RECQL
SCHEMBL8587196 0.75 GRIA4 (0.44) MMP8MMP12MMP13MEN1KMT2A
SCHEMBL3082582 0.75 RECQL (0.53) CA2CA1CA9CA12RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642270-B2 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-01-05 US disclosed
EP-1937681-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 EP disclosed
WO-2007033232-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO disclosed
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR CA2 1834/4885CA1 4217/4885CA9 2551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.